Introduction
Angiogenesis is a complex multistep process that involves outsprouting of vascular endothelial cells from existing vessels. This is critical for embryonic development, growth, endometrial and placental proliferation, wound healing and revascularisation of ischaemic tissues. Angiogenesis is also a central feature of many important diseases including cancer, rheumatoid arthritis, atherosclerosis and ocular neovascularisation. Neovascular diseases of the retina include retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration, conditions which are leading causes of blindness in developed countries. [1] [2] [3] Conventional treatments for these disorders are based on laser photocoagulation and cryotherapy, which are themselves inherently destructive, and have significant potential to adversely affect vision. 4, 5 Perhaps more importantly, the effects of these therapies are rarely sustained, and they do not control the pro-angiogenic mechanisms arising from the underlying disease. Advances in the understanding of the pathophysiology of angiogenesis have identified disturbances in a multistep process involving complex interactions between growth factors, extracellular matrix, and
and iris pigment epithelium. AAV-mediated GFP expression was evident in ganglion cells and cells of the inner nuclear layer of the retina. Vector-mediated sFlt-1 expression was confirmed by ELISA of pooled homogenised whole eyes. Injection of either vector expressing sFlt-1 resulted in a reduction in the number of neovascular endothelial cells by 56% and 52% for adenovirus and AAV vectors, respectively (P Ͻ 0.05). Local gene transfer of sFlt-1 consistently inhibits experimental retinal neovascularisation by approximately 50% and offers a powerful novel approach to the clinical management of retinal neovascular disorders.
Gene Therapy (2002) 9, 320-326. DOI: 10.1038/sj/gt/3301680 cellular components, the net outcome being determined by the balance of angiogenic and angiostatic elements. 6 Vascular endothelial growth factor (VEGF) is a potent endothelial cell-specific mitogen that plays a critical role in angiogenesis. 7, 8 VEGF is a 46-kDa homodimeric glycopeptide that is expressed by several different ocular cell types including pigment epithelial cells, pericytes, vascular endothelial cells, neuroglia and ganglion cells, 7, [9] [10] [11] and in specific spatial and temporal patterns during retinal development. 12 Expression of VEGF is upregulated by hypoxia in vitro 13 and in vivo. 10 It acts via specific fmslike receptors, Flt-1 and Flk-1/KDR, which are highaffinity receptor tyrosine kinases expressed on vascular endothelial cells (amongst others 14 ) , and leads to endothelial cell proliferation, migration, and increased vasopermeability. VEGF levels are increased in experimental models of retinal ischaemia, 9, 15 in patients with proliferative diabetic retinopathy, [16] [17] [18] and retinal vein occlusion. 17 Injection of VEGF into the eyes of nonhuman primates produces iris neovascularisation 20 and overexpression of VEGF by photoreceptors in transgenic mice causes retinal neovascularization. 21 Conversely, antagonists of VEGF inhibit experimental retinal 8, 22 and iris 23 neovascularisation. A soluble truncated form of the VEGF receptor Flt-1, sFlt-1, is the only known endogenous specific inhibitor of VEGF and has attracted considerable attention for its potential clinical application in the inhibition of angiogenesis. [24] [25] [26] [27] [28] sFlt-1, which lacks the membrane-proximal imunoglobulin-like domain, the transmembrane spanning region and the intracellular tyrosine-kinase domain, is generated by alternative splicing. The angiostatic activity of sFlt-1 results from inhibition of VEGF by two mechanisms. It causes both sequestration of VEGF, to which it binds with high affinity, and forms inactive heterodimers with membranespanning isoforms of the VEGF receptors Flt-1 and KDR. 24, 29 Though potentially efficaceous, systemic administration of inhibitors of angiogenesis may cause adverse effects, particularly in a population of patients, many of whom are already at increased risk of ischaemic heart disease, cerebrovascular and peripheral vascular disease. For this reason, local delivery of angiostatic agents offers significant potential advantages. Repeated intravitreal injections of a neutralizing anti-VEGF monoclonal antibody has been shown to reduce iris neovascularisation in a primate model of retinal ishaemia. 23 Inhibition of VEGF by repeated intravitreal injections of recombinant soluble VEGF-receptor (sFlt-1) chimeric proteins 25 and antisense oligodeoxynucleotides 22 have also been shown to reduce retinal neovascularisation in oxygen-induced retinopathy in mice by an average of 50% and 30%, respectively. However, effective control in patients with retinal neovascular disorders is likely to require the continuous presence of the antagonist. The relatively short half-life of angiostatic proteins delivered by intravitreal injection is such that frequently repeated administration would be necessary to maintain therapeutic levels. 30 This approach also carries a high cumulative risk of local complications, including intraocular infection, vitreous haemorrhage and retinal detachment. The implantation of sustainedrelease devices into the vitreous offers an alternative strategy but is associated with similar adverse effects. 31 In contrast, local gene transfer offers the possibility of targeted and sustained delivery of therapeutic agents following a single procedure. In this study we show that localised expression of sFlt-1 by gene transfer inhibits retinal neovascularisation in a murine model of ischaemic retinopathy and demonstrate the feasibility of a gene transfer approach to the control of angiogenesis in retinal neovascular disorders.
Results

Reporter gene expression by adenovirus and AAV vectors
In this study we used a well-characterised murine model of ischaemia-induced retinal neovascularisation. In order to determine the pattern of transgene expression following intra-ocular administration of Ad or AAV (serotype 2) vectors in this model, we injected into the vitreous vectors encoding GFP reporter genes driven by a CMV promoter. Previous experiments have indicated that Admediated expression is relatively immediate and transient, whereas AAV-mediated expression is delayed and sustained. 32 In order to coordinate the peak of expression of sFlt-1 by each vector with the period of most active angiogenesis in this model (postnatal day (p)12 to p19) we chose to use different injection time-points for each vector system. We injected the Ad vector at p12 because we anticipated expression to be maximal within a few days but rapidly attenuated thereafter, and injected the AAV vector at p2 to compensate for the expected delay in transgene expression. We enucleated and analysed the Gene Therapy eyes for vector-mediated expression at p16, 4 days after the onset of ischaemia-induced retinal neovascularisation. In eyes of mice injected with Ad.CMV.GFP, reporter gene expression was evident in cells of the corneal endothelium, iris pigment epithelium and ciliary epithelium (Figure 1b ), but not in the retina (except for a very small number of cells in the inner nuclear layer). In eyes of mice injected with AAV.CMV.GFP, expression was evident in retinal cells across a large area of the posterior pole (Figure 1d ), most prominently in the ganglion cell layer and inner nuclear layer, but also in a small number of photoreceptor cells in the outer nuclear layer. There was no evidence of gene transfer to ciliary epithelial or corneal endothelial cells by AAV of this serotype. No GFP fluorescence was observed in the anterior segment (Figure 1a ) or the retina (Figure 1c ) of uninjected eyes.
Expression of sFlt-1 in vivo
We next generated Ad and AAV vectors expressing sFlt-1 under the control of a CMV promoter. The integrity of each expression cassette was verified by transduction of 293T cells in vitro, and Western blotting for sFlt-1. We then injected mice at p12 and p2 for Ad and AAV vectors respectively, as performed for parallel vectors encoding GFP. Eyes were removed at p16, and analysed for expression of sFlt-1 by enzyme-linked immunosorbent assay (ELISA). Concentrations of sFlt-1 were measured in homogenates of pooled whole eyes. In eyes injected with Ad.CMV.sFlt-1 (n = 6), sFlt-1 was detected at a concentration of 72 ng/ml. In eyes injected with AAV.CMV.sFlt-1 (n = 4), sFlt-1 was detected at a concentration of 0.1
Figure 1 Fluorescence micrographs showing pattern of GFP reporter gene expression after intravitreal injection of Adenovirus and AAV vectors in murine ischaemia-induced retinopathy. Mice were killed at post-natal day (p)16. Enucleated eyes were fixed and 20-m cryosections were counterstained with propridium iodide. (a) Anterior segment and (c) retina of control uninjected eyes. No GFP fluorescence is observed. (b) Anterior segment after intravitreal injection of Ad.CMV.GFP at p12. Efficient GFP expression is demonstrated in corneal endothelium (end), trabecular meshwork (tm) iris pigment epithelium (ipe) and ciliary epithelium (ce). GFP expression is not seen in corneal epithelium (ep), corneal stroma (s) or retina (r). (d) Retina after injection of AAV.CMV.GFP at p2. GFP fluorescence is evident primarily in ganglion cell layer (gcl) and inner nuclear layer (inl). GFP positive photoreceptor cells are also present in the outer nuclear layer (onl).
ng/ml. sFlt-1 was undetectable in pooled uninjected eyes (n = 6). Attempts to localise sFlt-1 by immunohistochemistry were unsuccessful probably because of technical difficulties localising soluble antigen.
Qualitative and quantitative analysis of retinal neovascularisation
We induced ischaemic retinopathy in mouse pups by exposure to high levels of oxygen from p7 to p12. Exposure of mouse pups to hyperoxia in this way causes extensive retinal capillary closure. Subsequent return to room air results in retinal ischaemia and VEGF-dependent pre-retinal neovascularisation in 100% of animals. Assessment of retinal flatmounts following terminal perfusion with dextran-conjugated FITC at p19 indicated fewer neovascular complexes in eyes injected with AAV.CMV.sFlt-1 and Ad.CMV.sFlt-1 than in uninjected eyes or in eyes injected with PBS, Ad.CMV.GFP or AAV.CMV.GFP ( Figure 2 ). We performed quantitative analysis of retinal neovascularisation by counting the number of vascular endothelial cell nuclei on the vitreal side of the inner limiting membrane of the retina in serial sections of eyes at p19. The mean (±s.e.m.) was 48.2 (4.1) in uninjected eyes (n = 7), 42.1 (5.0) in eyes injected with PBS (n = 7), 34.8 (3.3) in eyes injected with Ad.CMV.GFP (n = 9), 21.4 (4.3) in eyes injected with Ad.CMV.sFlt-1 (n = 7) (P Ͻ 0.05), 52.1 (6.9) in eyes injected with AAV.CMV.GFP (n = 7), and 23.3 (6.6) in eyes injected with AAV.CMV.sFlt-1 (n = 6) (P Ͻ 0.05) indicating a significant reduction in neovascularisation following local delivery of a gene encoding sFlt-1 (Figure 3) . (Figure 4a-c) . This vascular pattern is preserved after intravitreal injection of Ad.CMV.sFlt-1 at p12 (Figure 4e-g ) or injection of AAV.CMV.sFlt-1 at p2 (Figure 4i-k) and there is no evidence of altered vascular permeability. To investigate possible adverse effects on retinal architecture, we used light microscopy to examine sections of normal (nonischaemic) mice injected in the same way (Figure 4d, h,  l) . The retina appeared normal and we observed no evidence of an inflammatory cell infiltrate.
Assessment of retinal toxicity
In order to determine any potential adverse effects of viral gene transfer of sFlt-1 on normal retinal vascular development or architecture we injected the vectors into the vitreous of normal (non-ischaemic) pups. To assess effects on retinal vasculature we analysed FITC-dextran perfused retinal flatmounts. In the uninjected eye of a normal mouse the vessels form a fine radial branching pattern in the superficial layer and a polygonal reticular pattern in the deep layer
Discussion
Adenovirus-mediated expression of sFlt-1 effectively inhibits tumour growth in mice when the vector is delivered regionally 27 or into a remote organ. 33 We have shown that local gene transfer and expression of sFlt-1 consistently inhibits experimental retinal neovascularisation by approximately 50% (52% and 56% for AAV and Ad vectors, respectively). At present, it is unclear whether residual neovascularisation is due to incomplete inhibition of the VEGF response, or rather from the uninhibited activity of an alternative angiogenic pathway. The ability of a VEGF receptor kinase inhibitor to completely prevent neovascularisation when delivered systemically in the same model suggests that improved gene delivery and expression might be expected to overcome this limitation. 8 It remains to be seen whether efficacy can also be enhanced by gene transfer of dual or multiple antiangiogenic factors. Our findings are consistent with previous studies of VEGF inhibition in which recombinant proteins have been delivered by repeated intravitreal injection. Retinal neovascularisation was reduced by 47% after repeated injection of recombinant sFlt-1 25 and by 31% after repeated injections of antisense oligodeoxynucleotides. 22 Neovascularisation in the murine model of ischaemiainduced retinopathy occurs as a short-lived response; after p21 no further proliferation occurs and the new vessels regress spontaneously. 34 Even in this model in which the neovascular response is relatively transient, delivery of sFlt-1 by gene transfer after a single procedure is at least as effective as repeated intravitreal injection. The advantage of a gene transfer approach in facilitating susGene Therapy tained inhibition is likely to be of even greater importance when applied to conditions in which there is a longer-term predilection to neovascularisation. Although AAV-mediated expression of sFlt-1 is likely to be sustained, the long-term effect on neovascularisation cannot be confirmed in this model and will need to be evaluated in further appropriate models and clinical studies.
We have evaluated the efficacy of two different viral vector systems with contrasting expression profiles. Although more rapid in onset of expression, most adenoviral vectors are less attractive than AAV vectors for clinical application because of their immunogenicity, toxicity, and short-lived expression. 35 The vectors also have contrasting spatial patterns of successful gene transfer and transgene expression. Intravitreal injection of adenoviral vectors results in transduction of the corneal endothelial cells, iris, ciliary body and trabecular meshwork. 36, 37 Transduction of retinal Muller cells has previously been reported after intravitreal injection of adenoviral vectors, [38] [39] [40] but is inefficient unless the injection is combined with a vitrectomy, 41 a procedure not performed in our study. We have not demonstrated tissue localisation of sFlt-1 by immunohistochemistry, but can speculate that a substantial proportion of soluble protein secreted by cells in the anterior segment and ciliary body may be directed by aqueous flow anteriorly through the pupil towards the trabecular meshwork. This pattern of expression may be particularly well suited to the delivery of sFlt-1 in the management of neovascularisation of the iris and iridocorneal angle. However, the efficacy of Ad vectors in reducing retinal neovascularisation also suggests that sFlt-1 diffuses posteriorly from the anterior segment across the vitreous body to the inner retina in quantities sufficient to achieve significant VEGF inhibition. In contrast, intravitreal injection of AAV almost exclusively results in reporter gene expression by cells in the retinal ganglion cell layer and inner nuclear layer, consistent with transfection of ganglion cells and Muller cells. The proximity of these cells to the developing neovascular complexes in the retina may explain a comparable angiostatic effect despite relatively low levels of sFlt-1 expression. The localisation of gene expression close to the site of pathology, and the known biological characteristics of gene transfer by AAV vectors makes this a highly attractive strategy for sustained therapy of retinal neovascularisation.
VEGF is implicated in retinal vascular development and acts as a survival factor for retinal vascular endothelium in vivo. 42 For this reason we investigated the effect of sFlt-1-mediated VEGF inhibition on retinal vascular development and architecture in the normal mouse. The development of the retinal vasculature in mice occurs during the first 2 weeks of life. 43 From p0 to p10 vessels develop radially by vasculogenesis from the optic disc to the ora serrata to form a superficial vascular network within the nerve fibre layer of the inner retina. From p4, vessels extend from these superficial vessels by angiogenesis towards the outer retina leading to the formation of a deep vascular plexus. We have demonstrated that the development of both superficial and deep retinal vascular networks is normal despite sFlt-1 expression by either vector system. We also found the retinal architecture to be unaffected. Although we observed no evidence of an inflammatory cell infiltrate in H&E-stained histological sections, an immune response to the adenoviral vector is well-described in the literature and is usually only apparent after immunophenotyping. 35 Whilst these results suggest that sFlt-1-mediated VEGF inhibition has no dramatic adverse effect on retinal vascular development or structure, there remains the possibility that sustained, complete or uncontrolled inhibiton of VEGF may cause undesirable effects on endothelial cell homeostasis. Incorporation of regulatable expression elements in the vector will minimise these possibilities, and such a strategy is currently being tested.
In addition to its central role in angiogenesis, 29 VEGF promotes vascular permeability through Flt-1 receptors. 44 By reducing vasopermeability, VEGF antagonsits such as sFlt-1 may have additional potential applications in the management of macular oedema, a common cause of visual loss in diabetes, 45 uveitis, 46 and after cataract surgery. 47 In conclusion, gene transfer of sFlt-1 consistently controls angiogenesis in experimental retinal neovascularisation. Our findings demonstrate the feasibility of an in vivo gene therapy approach to the clinical management of angiogenesis in the retina.
Materials and methods rAAV vector construction and production
A recombinant AAV plasmid vector containing the sFlt-1 cDNA driven by a CMV promoter and flanked at the 3' end with a SV40 polyadenylation signal was constructed. The cDNA encoding the sFlt-1 was amplified by PCR from a recombinant adenovirus vector encoding the sFlt-1 DNA (a gift from Dr R Crystal, Cornell University, New York, NY, USA) using the forward primer (TCGGGATCCTCGCCACCATGGTCAGCTACTGGGAC ACC) which incorporated a BamHI site and a reverse primer (ATAGCGGCCGCTTAATGTTTTACATTACTTT GTGTGGT) which incorporated a NotI site. The PCR was carried out using the proof-reading enzyme Pfu polymerase (Stratagene, Amsterdam, The Netherlands). The 2.1 kb product was digested with BamHI and NotI, then sub-cloned into the mammalian expression cassette pEGFP-N1 (Clontech, Basingstoke, UK) vector by substituting the BamHI-NotI EGFP cDNA fragment with the PCR amplified fragment. The sFlt-1 cDNA was verified by sequencing (Lark Technologies, Saffron Walden, UK). The resulting expression cassette was subcloned into a derivative of AAV plasmid psub201 48 that was deleted for all viral genes to produce the plasmid AAV.CMV.sFlt-1.
Recombinant AAV plasmid expressing GFP driven by the CMV promoter (pHAV 5.5) was produced using the replicating amplicon system described previously, 49 with a slight modification in the purification procedure: the CsCl gradient purification step was replaced with an iodoxianol gradient followed by a one-step affinity purification procedure on a Heparin column. 50 Analysis of sFlt-1 expression by rAAV.CMV.sFlt-1 in vitro 293 cells were cultured in six-well culture plates with DMEM (Gibco BRL, Paisley, UK) supplemented with 10% foetal bovine serum. The cells were allowed to grow until they reached approximately 80% confluence at which point they were infected with either rAAV.CMV.sFlt-1 (2 l/well, 5 × 10 10 particles) or rAAV-CMV-GFP ( (2 l/well, 5 × 10 10 particles) as control. After 48 h, the conditioned medium was collected and the proteins greater then 10 kDa were concentrated up using a Centricon YM-10 (Millipore, Bedford, MA, USA). Protein concentrations were determined using a BioRad protein assay (BioRad). Protein samples (50 g) were solubilised in SDS-loading buffer and subjected to SDS-polyacrylamide (10%) gel electrophoresis. Protein was transferred on to a nylon membrane (Millipore, Bedford, MA, USA) and the blot was sequentially incubated in primary antibody (1:500 goat anti-sFlt, R&D Systems, Abingdon, UK) and secondary antibody horseradish peroxidase-conjugated rabbit antigoat (1/1000 Dako, Carpinteria, CA, USA). The ECL kit (Amersham, Little Chalfont, UK) was used to generate a chemiluminescent signal.
Murine model of oxygen-induced retinopathy
Litters of C57Bl/6J mice (Harlan, Bicester, UK) were used. All animals were treated in a humane manner and were managed in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Murine oxygen-induced retinopathy is a highly reproducible model of VEGF-dependent 9 retinal neovascularisation and is described elswhere. 34 Briefly, ischaemic retinopathy was induced by exposure of mouse pups to 75 ± 2% oxygen from p7 to p12 in a sealed incubator along with nursing mothers.
Intravitreal injections
Mice were anaesthetised with intraperitoneal injection of 0.2 ml Hypnorm (Janssen Pharmaceutical, Oxford, UK), and Hypnovel (Roche, Welwyn Garden City, UK) mixed 1:1:60 with distilled water. The palpebral fissure was opened with a No. 11 scalpel blade and the pupil dilated with topical 1% Tropicamide (1% Mydriacyl; Alcon Laboratories, Watford, UK). The procedure was performed under an operating microscope. The fundus was visual-ised by means of a contact lens system consisting of a drop of 1% hypromellose solution on the cornea, covered with a glass coverslip. The tip of a 10-mm 34-guage steel needle, mounted on a 10-l Hamilton syringe, was advanced under direct vision through the sclera, 1mm posterior to the corneoscleral limbus, into the vitreous and approximately 1 l of viral suspension was injected into the vitreous cavity. Eyes were injected with AAV expressing sFlt-1 (AAV.CMV.sFlt-1) at p2 or adenovirus expressing sFlt-1 (Ad.CMV.sFlt-1) at p12, immediately upon removal from the incubator. Control eyes were uninjected, injected with PBS, AAV expressing green fluorescent protein (AAV.CMV.GFP) or adenovirus expressing green fluorescent protein (Ad.CMV.GFP).
Imaging of GFP expression
Mice were killed at p16 by cervical dislocation. Eyes were enucleated, fixed in 4% paraformaldehyde for 1 h, cryoprotected in 20% sucrose, embedded in optimal cutting temperature medium and frozen in liquid nitrogen. 20-m sections were counterstained with propidium iodide, mounted in fluorescent mounting medium and viewed by fluorescence microscopy.
Enzyme linked immunosorbent assay
Pooled whole eyes of mice killed at p16 were ground manually in 150-l assay buffer. The resulting suspension was centrifuged at 4000 r.p.m. for 5 min and the supernatant assayed for total sFlt-1 using a commercial total sFlt-1 Test Kit (RELIATech, Braunschweig, Germany).
Fluorescein-dextran perfused fused whole retina mounts
At p19, cardiac perfusion was performed with 1 ml PBS containing 50 mg/ml fluorescein-labelled dextran (2 × 10 6 average molecular weight, Sigma, St Louis, MO, USA), clarified by centrifugation for 5 min at 10 000 r.p.m. 34, 51 The eyes were enucleated and fixed in 4% paraformaldehyde for 1 h. The cornea and lens were removed and the retina dissected from the eyecup. The retina was cut radially into four quadrants and flat-mounted in Aquamount under a coverslip for examination by fluorescence microscopy at ×200/400 magnification.
Quantification of retinal neovascularisation
Eyes were enucleated, fixed in 4% paraformaldehyde, processed through a graded series of alcohols and embedded in paraffin. Seven 6-m sagittal sections, each 30 m apart, on each side of optic nerve were stained with periodic acid Schiff and haematoxylin. The number of neovascular endothelial cell nuclei on the vitreous side of the inner limiting membrane of the retina in each section was counted at ×400 magnification using a masked protocol. The mean number of cell nuclei per section per eye was used as a single experimental value. The mean numbers of neovascular cell nuclei in each treatment group were compared. Statistical analysis was performed using ANOVA and Student's t test with Bonferroni's correction for multiple comparisons. A P-value of Յ0.05 was considered statistically significant.
Retinal toxicity
The vectors expressing sFlt-1 were injected into the vitreous of normal (non-ischaemic) pups. Ad.CMV.sFlt-1 was injected at p12 and AAV.CMV.sFlt-1 at p2. Mice were killed at p19. We performed FITC-dextran perfused Gene Therapy flatmounts to investigate vascular development and light microscopy of H&E stained 6-m sections of paraffinembedded eyes to analyse retinal architecture, inflammatory cell infiltration and retinal thickening.
